- Home
- BIOA vs ACHV Comparison
BIOA vs ACHV Comparison
Compare BIOA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- ACHV
- Stock Information
- Founded
- BIOA 2015
- ACHV N/A
- Country
- BIOA United States
- ACHV United States
- Employees
- BIOA N/A
- ACHV N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BIOA Health Care
- ACHV Health Care
- Exchange
- BIOA Nasdaq
- ACHV Nasdaq
- Market Cap
- BIOA 175.7M
- ACHV 153.8M
- IPO Year
- BIOA 2024
- ACHV N/A
- Fundamental
- Price
- BIOA $5.45
- ACHV $3.04
- Analyst Decision
- BIOA Hold
- ACHV Strong Buy
- Analyst Count
- BIOA 4
- ACHV 2
- Target Price
- BIOA $5.67
- ACHV $16.00
- AVG Volume (30 Days)
- BIOA 189.4K
- ACHV 1.0M
- Earning Date
- BIOA 11-06-2025
- ACHV 11-06-2025
- Dividend Yield
- BIOA N/A
- ACHV N/A
- EPS Growth
- BIOA N/A
- ACHV N/A
- EPS
- BIOA N/A
- ACHV N/A
- Revenue
- BIOA $3,863,000.00
- ACHV N/A
- Revenue This Year
- BIOA N/A
- ACHV N/A
- Revenue Next Year
- BIOA N/A
- ACHV N/A
- P/E Ratio
- BIOA N/A
- ACHV N/A
- Revenue Growth
- BIOA N/A
- ACHV N/A
- 52 Week Low
- BIOA $2.88
- ACHV $1.84
- 52 Week High
- BIOA $26.62
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- BIOA 63.40
- ACHV 53.82
- Support Level
- BIOA $4.88
- ACHV $2.93
- Resistance Level
- BIOA $5.34
- ACHV $3.17
- Average True Range (ATR)
- BIOA 0.26
- ACHV 0.16
- MACD
- BIOA 0.04
- ACHV -0.01
- Stochastic Oscillator
- BIOA 95.06
- ACHV 50.94
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.